{"id":1891,"date":"2010-11-04T10:31:55","date_gmt":"2010-11-04T14:31:55","guid":{"rendered":"http:\/\/sciencebusiness.technewslit.com\/?p=1891"},"modified":"2010-11-04T10:33:00","modified_gmt":"2010-11-04T14:33:00","slug":"biotechs-awarded-michael-j-fox-foundation-grants","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=1891","title":{"rendered":"Biotechs Awarded Michael J. Fox Foundation Grants"},"content":{"rendered":"<figure id=\"attachment_200\" aria-describedby=\"caption-attachment-200\" style=\"width: 200px\" class=\"wp-caption alignleft\"><a href=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/07\/Neuron_NIH_200.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-200\" title=\"Neuron_NIH_200\" src=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/07\/Neuron_NIH_200.jpg\" alt=\"Neuron illustration (NIH)\" width=\"200\" height=\"200\" srcset=\"https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/07\/Neuron_NIH_200.jpg 200w, https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/07\/Neuron_NIH_200-150x150.jpg 150w\" sizes=\"auto, (max-width: 200px) 100vw, 200px\" \/><\/a><figcaption id=\"caption-attachment-200\" class=\"wp-caption-text\">(National Institute on Aging, NIH)<\/figcaption><\/figure>\n<p>Two biotechnology companies report today awards of grants from the <a href=\"http:\/\/www.michaeljfox.org\/\">Michael J. Fox Foundation<\/a> (MJFF). The foundation supports research on therapies for Parkinson&#8217;s disease.<\/p>\n<p>Adolor Corporation in Exton, Pennsylvania says it received a <a href=\"http:\/\/phx.corporate-ir.net\/phoenix.zhtml?c=120919&amp;p=irol-newsArticle&amp;ID=1491761&amp;highlight=\">second round of funding<\/a> by MJFF to support the development of treatments for <a href=\"http:\/\/www.psychiatrictimes.com\/display\/article\/10168\/55966\">levadopa (l-DOPA)-induced dyskinesia<\/a> (LID) associated with Parkinson&#8217;s disease. The $363,400 award will be paid over a period of 18 months.<\/p>\n<p>LID is characterized by a variety of hyperkinetic movements and  complicates the use of levodopa therapy for the treatment of Parkinson&#8217;s  symptoms. The company cites evidence that suggests increased opioid peptide transmission in the basal ganglia might underlie dyskinesia after chronic l-DOPA treatment and that opioid antagonists might be useful in supporting l-DOPA therapy for Parkinson&#8217;s disease. Adalor says it developed compounds shown to be effective, after oral administration, in well-validated, non-human primate preclinical models of LID, confirmed by three independent laboratories.<\/p>\n<p><a href=\"http:\/\/www.athersys.com\/\">Athersys Inc.<\/a> in Cleveland, Ohio says it secured a $140,000 grant from MJFF to advance its MultiStem product platform as a potential treatment for Parkinson&#8217;s disease. MultiStem consists of clinical grade non-embryonic stem cells obtained from bone marrow that have the potential to produce a range of factors and form multiple cell types. MultiStem&#8217;s primary mechanism appears to be the production of therapeutic proteins and other molecules produced in response to inflammation and tissue damage.<\/p>\n<p>The company says research funded by the grant is expected to confirm and extend previous observations about the efficacy of MultiStem in rodent models of Parkinson&#8217;s disease.<\/p>\n<p style=\"text-align: center;\">*\u00a0\u00a0\u00a0\u00a0 *\u00a0\u00a0\u00a0\u00a0 *<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Two biotechnology companies report today awards of grants from the Michael J. Fox Foundation (MJFF). The foundation supports research on therapies for Parkinson&#8217;s disease. Adolor Corporation in Exton, Pennsylvania says it received a second round of funding by MJFF to support the development of treatments for levadopa (l-DOPA)-induced dyskinesia (LID) associated with Parkinson&#8217;s disease. The [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[31,21,38,48],"class_list":["post-1891","post","type-post","status-publish","format-standard","hentry","category-finance","tag-biomedical","tag-biotech","tag-grant","tag-stem-cells"],"_links":{"self":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/1891","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1891"}],"version-history":[{"count":3,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/1891\/revisions"}],"predecessor-version":[{"id":1894,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/1891\/revisions\/1894"}],"wp:attachment":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1891"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1891"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1891"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}